• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    2/22/23 8:06:01 AM ET
    $ACON
    $CGTX
    $CMMB
    $CRL
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • Windtree Therapeutics (NASDAQ:WINT) stock increased by 28.8% to $0.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $9.5 million.
    • Sorrento Therapeutics (NASDAQ:SRNE) shares moved upwards by 24.8% to $0.48. The market value of their outstanding shares is at $263.5 million.
    • MediciNova (NASDAQ:MNOV) stock increased by 16.52% to $2.68. The market value of their outstanding shares is at $131.4 million.
    • Cognition Therapeutics (NASDAQ:CGTX) shares moved upwards by 16.2% to $1.9. The company's market cap stands at $55.0 million.
    • Immix Biopharma (NASDAQ:IMMX) stock rose 15.45% to $2.39. The company's market cap stands at $33.2 million.
    • Spruce Biosciences (NASDAQ:SPRB) shares increased by 12.5% to $2.7. The company's market cap stands at $63.6 million.

    Losers

    • Monopar Therapeutics (NASDAQ:MNPR) stock decreased by 17.0% to $2.78 during Wednesday's pre-market session. The company's market cap stands at $35.9 million.
    • Quoin Pharmaceuticals (NASDAQ:QNRX) shares decreased by 15.97% to $1.0. The market value of their outstanding shares is at $4.8 million.
    • Chemomab Therapeutics (NASDAQ:CMMB) shares decreased by 14.85% to $1.95. The market value of their outstanding shares is at $22.4 million.
    • Aclarion (NASDAQ:ACON) shares fell 11.71% to $0.68. The market value of their outstanding shares is at $5.3 million.
    • eFFECTOR Therapeutics (NASDAQ:EFTR) stock declined by 10.01% to $0.45. The company's market cap stands at $18.9 million.
    • Charles River (NYSE:CRL) shares fell 10.0% to $219.25. The market value of their outstanding shares is at $11.1 billion. The company's, Q4 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $CGTX
    $CMMB
    $CRL

    CompanyDatePrice TargetRatingAnalyst
    Immix Biopharma Inc.
    $IMMX
    3/9/2026$23.00Mkt Outperform
    Citizens
    Immix Biopharma Inc.
    $IMMX
    2/9/2026$14.00Outperform
    Mizuho
    Monopar Therapeutics Inc.
    $MNPR
    1/9/2026$115.00Overweight
    Morgan Stanley
    Spruce Biosciences Inc.
    $SPRB
    12/23/2025$283.00Outperform
    Oppenheimer
    Charles River Laboratories International Inc.
    $CRL
    12/15/2025$225.00Neutral → Buy
    BofA Securities
    Spruce Biosciences Inc.
    $SPRB
    12/3/2025$160.00Market Perform → Outperform
    Leerink Partners
    Charles River Laboratories International Inc.
    $CRL
    11/17/2025Hold → Buy
    Argus
    Monopar Therapeutics Inc.
    $MNPR
    11/14/2025Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $ACON
    $CGTX
    $CMMB
    $CRL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate update

    3/9/26 7:05:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

    Mr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including commercial leadership roles for 21 new product launches. Mr. Hooks previously served as Chief Commercial Officer of Applied Therapeutics and was responsible

    3/9/26 7:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immix Biopharma to Participate in Upcoming Investor Conferences

    LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host investor meetings at the following upcoming institutional investor conferences: Leerink Partners 2026 Global Healthcare Conference being held March 8-11, 2026 in Miami Beach, FL. The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami Beach, FL. Company management will host one-on-one meetings during the conferences. Interested investors should contact their Leerink or Citizens representative to request meetings. A link to access replays, when a

    3/3/26 8:45:00 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $CGTX
    $CMMB
    $CRL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens initiated coverage on Immix Biopharma with a new price target

    Citizens initiated coverage of Immix Biopharma with a rating of Mkt Outperform and set a new price target of $23.00

    3/9/26 9:07:22 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Immix Biopharma with a new price target

    Mizuho initiated coverage of Immix Biopharma with a rating of Outperform and set a new price target of $14.00

    2/9/26 7:01:42 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Monopar Therapeutics with a new price target

    Morgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00

    1/9/26 9:05:54 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $CGTX
    $CMMB
    $CRL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Commercial Officer Hooks Corwin Dale

    4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

    3/9/26 4:08:18 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hooks Corwin Dale

    3 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

    3/9/26 4:07:17 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corporate Executive VP & COO Girshick Birgit gifted 328 shares (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    3/5/26 5:18:17 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ACON
    $CGTX
    $CMMB
    $CRL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Corp Strategy & Develop Laplume Joseph W bought $4,364 worth of shares (25 units at $174.54), increasing direct ownership by 0.09% to 27,448 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    3/4/26 4:39:28 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    12/29/25 12:15:31 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Rachman Ilya M bought $4,976 worth of shares (746 units at $6.67), increasing direct ownership by 0.07% to 1,141,683 units (SEC Form 4)

    4 - Immix Biopharma, Inc. (0001873835) (Issuer)

    12/10/25 6:49:30 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $CGTX
    $CMMB
    $CRL
    SEC Filings

    View All

    SEC Form 10-K filed by Medicinova Inc

    10-K - MEDICINOVA INC (0001226616) (Filer)

    3/10/26 5:15:50 PM ET
    $MNOV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Spruce Biosciences Inc.

    424B5 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

    3/9/26 7:31:48 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Spruce Biosciences Inc.

    S-8 - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

    3/9/26 7:29:22 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $CGTX
    $CMMB
    $CRL
    Leadership Updates

    Live Leadership Updates

    View All

    Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company's Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate update

    3/9/26 7:05:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

    Mr. Hooks Brings Over Three Decades of Comprehensive Biopharmaceutical Marketing and Commercialization Expertise, Including the Launch of 21 New Products Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer. Mr. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including commercial leadership roles for 21 new product launches. Mr. Hooks previously served as Chief Commercial Officer of Applied Therapeutics and was responsible

    3/9/26 7:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $CGTX
    $CMMB
    $CRL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Chemomab Therapeutics Ltd.

    SC 13D/A - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    11/29/24 3:04:59 PM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Chemomab Therapeutics Ltd.

    SC 13G - Chemomab Therapeutics Ltd. (0001534248) (Subject)

    11/21/24 10:59:28 AM ET
    $CMMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $CGTX
    $CMMB
    $CRL
    Financials

    Live finance-specific insights

    View All

    Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

    – Fourth-Quarter Revenue of $994.2 Million and Full-Year Revenue of $4.02 Billion – – Fourth-Quarter GAAP Loss per Share of $(5.62) and Non-GAAP Earnings per Share of $2.39 – – Full-Year GAAP Loss per Share of $(2.91) and Non-GAAP Earnings per Share of $10.28 – – Provides 2026 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2025 and provided guidance for 2026. For the quarter, revenue was $994.2 million, a decrease of 0.8% from $1,002.5 million in the fourth quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.9%, and the divestiture of a small Safety Assessm

    2/18/26 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

    Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2025 financial results and provide 2026 guidance on Wednesday, February 18th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 18th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leadi

    1/21/26 4:30:00 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

    CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (NASDAQ:SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1].

    1/18/26 7:02:00 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $CGTX
    $CMMB
    $CRL
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care